polymyositis

Summary

Summary: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)

Top Publications

  1. ncbi Inflammatory myopathies: evaluation and management
    Steven A Greenberg
    Department of Neurology, Brigham and Women s Hospital, Department of Neurology, Division of Neuromuscular Disease, Brigham and Women sHospital, and Harvard Medical School, Boston, MA 02115, USA
    Semin Neurol 28:241-9. 2008
  2. ncbi Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis
    ANDREW L MAMMEN
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann N Y Acad Sci 1184:134-53. 2010
  3. ncbi Polymyositis and dermatomyositis
    Marinos C Dalakas
    Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1382, USA
    Lancet 362:971-82. 2003
  4. ncbi Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis
    S A Greenberg
    Department of Neurology, Division of Neuromuscular Disease, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Genes Immun 13:207-13. 2012
  5. ncbi p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis
    Anna Nogalska
    Department of Neurology, USC Neuromuscular Center, Good Samaritan Hospital, University of Southern California Keck School of Medicine, Los Angeles, CA 90017 1912, USA
    Acta Neuropathol 118:407-13. 2009
  6. ncbi Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study
    Nobuo Wakata
    Fourth Department of Internal Medicine, Toho University, School of Medicine, Tokyo, Japan
    Int J Dermatol 41:729-34. 2002
  7. pmc Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies
    Lisa G Rider
    Environmental Autoimmunity Group, Office of Clinical Research, National Institute of Environmental Health Sciences NIH, 10 Center Drive, Bethesda, MD 20892 1301, USA
    Arthritis Care Res (Hoboken) 62:465-72. 2010
  8. ncbi Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis
    Min Wook So
    Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Rheumatol 38:2432-5. 2011
  9. ncbi Review: An update on inflammatory and autoimmune myopathies
    M C Dalakas
    Department of Neurosciences, Imperial College, London, UK
    Neuropathol Appl Neurobiol 37:226-42. 2011
  10. pmc Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial
    Chester V Oddis
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Arthritis Rheum 65:314-24. 2013

Detail Information

Publications262 found, 100 shown here

  1. ncbi Inflammatory myopathies: evaluation and management
    Steven A Greenberg
    Department of Neurology, Brigham and Women s Hospital, Department of Neurology, Division of Neuromuscular Disease, Brigham and Women sHospital, and Harvard Medical School, Boston, MA 02115, USA
    Semin Neurol 28:241-9. 2008
    The inflammatory myopathies, including dermatomyositis, inclusion body myositis, and polymyositis, are poorly understood autoimmune diseases affecting skeletal muscle...
  2. ncbi Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis
    ANDREW L MAMMEN
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann N Y Acad Sci 1184:134-53. 2010
    Dermatomyositis (DM) and polymyositis (PM) are autoimmune myopathies characterized clinically by proximal muscle weakness, muscle inflammation, extramuscular manifestations, and frequently, the presence of autoantibodies...
  3. ncbi Polymyositis and dermatomyositis
    Marinos C Dalakas
    Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1382, USA
    Lancet 362:971-82. 2003
    ..and demographic features, they can be differentiated into three major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myositis...
  4. ncbi Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis
    S A Greenberg
    Department of Neurology, Division of Neuromuscular Disease, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Genes Immun 13:207-13. 2012
    ..mRNA, disease activity and treatment effects in a longitudinal study of patients with dermatomyositis (DM) or polymyositis (PM). In all, 24 patients with DM or PM were followed for up to 6 years (mean of 1...
  5. ncbi p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis
    Anna Nogalska
    Department of Neurology, USC Neuromuscular Center, Good Samaritan Hospital, University of Southern California Keck School of Medicine, Los Angeles, CA 90017 1912, USA
    Acta Neuropathol 118:407-13. 2009
    ..The prominent p62 immunohistochemical positivity and pattern diagnostically distinguish s-IBM from polymyositis and dermatomyositis...
  6. ncbi Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study
    Nobuo Wakata
    Fourth Department of Internal Medicine, Toho University, School of Medicine, Tokyo, Japan
    Int J Dermatol 41:729-34. 2002
    b>Polymyositis and dermatomyositis in association with malignancy are paraneoplastic syndromes, but the incidence, treatment and factors that predict associated cancer and its prognosis all remain unclear.
  7. pmc Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies
    Lisa G Rider
    Environmental Autoimmunity Group, Office of Clinical Research, National Institute of Environmental Health Sciences NIH, 10 Center Drive, Bethesda, MD 20892 1301, USA
    Arthritis Care Res (Hoboken) 62:465-72. 2010
    To validate manual muscle testing (MMT) for strength assessment in juvenile and adult dermatomyositis (DM) and polymyositis (PM).
  8. ncbi Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis
    Min Wook So
    Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Rheumatol 38:2432-5. 2011
    To define the standardized incidence ratio (SIR) of malignancy and factors associated with malignancies in Korean patients with dermatomyositis (DM) and polymyositis (PM).
  9. ncbi Review: An update on inflammatory and autoimmune myopathies
    M C Dalakas
    Department of Neurosciences, Imperial College, London, UK
    Neuropathol Appl Neurobiol 37:226-42. 2011
    ..an update on the diagnosis of the main subtypes of inflammatory myopathies including dermatomyositis (DM), polymyositis (PM), necrotizing autoimmune myositis (NAM) and sporadic inclusion body myositis (sIBM)...
  10. pmc Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial
    Chester V Oddis
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Arthritis Rheum 65:314-24. 2013
    ..To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis patients...
  11. ncbi Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study
    C F Kuo
    Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
    Br J Dermatol 165:1273-9. 2011
    Nationwide data on the epidemiology of dermatomyositis (DM) and polymyositis (PM) were limited.
  12. pmc Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis
    M Aleksza
    Third Department of Internal Medicine, University of Debrecen, Medical and Health Centre, Debrecen, Hungary
    Ann Rheum Dis 64:1485-9. 2005
    To investigate the intracellular and soluble cytokine levels and T cell subsets in peripheral blood of patients with active and inactive polymyositis and dermatomyositis.
  13. ncbi Interstitial lung disease in polymyositis and dermatomyositis
    M Hirakata
    Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    Curr Opin Rheumatol 12:501-8. 2000
    Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders...
  14. ncbi Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota
    Floranne C Wilson
    Division of Rheumatology, Mayo Clinic, College of Medicine, Rochester, Minnesota 55905, USA
    J Rheumatol 35:445-7. 2008
    To determine the incidence and prevalence of sporadic inclusion body myositis (sIBM) and polymyositis (PM) in a population-based study.
  15. ncbi Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study
    R Buchbinder
    Department of Clinical Epidemiology, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144
    Ann Intern Med 134:1087-95. 2001
    ..Such issues as the legitimacy of a myositis diagnosis and distinction among myositis subgroups in previous population-based studies remain unresolved...
  16. ncbi Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases
    Kuang Hui Yu
    Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, 5, Fu Shin St, Kuei Shan 333, Tao Yuan, Taiwan
    Clin Rheumatol 30:1595-601. 2011
    To estimate the mortality rate and identify factors predicting survival in patients with polymyositis (PM) and dermatomyositis (DM)...
  17. ncbi Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis
    Kohei Azuma
    Division of Rheumatology and Allergology, Department of Internal Medicine, St Marianna University School of Medicine, 2 16 1 Sugao, Miyamae ku, Kawasaki, Kanagawa, 216 8511, Japan
    Mod Rheumatol 21:178-83. 2011
    ..A total of 145 patients diagnosed with either dermatomyositis/polymyositis (DM/PM) or CADM at our institute between 1984 and 2002 were enrolled in the study...
  18. pmc Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies
    M Tucci
    DIMO, Department of Internal Medicine and Clinical Oncology, University of Bari, Italy
    Clin Exp Immunol 146:21-31. 2006
    ..the role of interleukin (IL)-18 in patients with inflammatory myopathies (IM) such as dermatomyositis (DM) and polymyositis (PM) in relation to the possible predominance of a Th1 immune response in their pathogenesis...
  19. ncbi Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences
    S Bernatsky
    Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada
    Ann Rheum Dis 68:1192-6. 2009
    To estimate the prevalence of polymyositis and dermatomyositis using population-based administrative data, the sensitivity of case ascertainment approaches and patient demographics and these parameters.
  20. ncbi Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis
    Masanori Funauchi
    Department of Neurology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
    J Rheumatol 33:903-6. 2006
    b>Polymyositis and dermatomyositis (PM/DM) are often complicated by interstitial pneumonitis (IP), which is an important cause of death...
  21. ncbi Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology
    Maryam Fathi
    Karolinska University Hospital, Solna, Sweden
    Arthritis Rheum 59:677-85. 2008
    To estimate predictors and long-term outcome of interstitial lung disease (ILD) in patients with polymyositis (PM) and dermatomyositis (DM).
  22. ncbi Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A
    Naoko Okiyama
    Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Arthritis Rheum 60:2505-12. 2009
    To explore new molecular targets in the treatment of polymyositis (PM) by examining a recently established murine model of PM, C protein-induced myositis (CIM), for involvement of an interleukin-6 (IL-6)/IL-17A pathway.
  23. pmc Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index
    Lisa G Rider
    Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD 20892 1301, USA
    Arthritis Rheum 60:3425-35. 2009
    ..We undertook this study to validate the Myositis Damage Index (MDI) in juvenile and adult myositis, to describe the degree and types of damage and to develop predictors of damage...
  24. ncbi Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies
    C Cappelletti
    Department of Neurology IV, Neurological Institute Foundation Carlo Besta, Via Celoria 11, 20133 Milan, Italy
    Neurology 76:2079-88. 2011
    Juvenile dermatomyositis (JDM), adult dermatomyositis, and polymyositis (PM) are idiopathic inflammatory myopathies (IIMs) characterized by muscle infiltration and specific muscle fiber alterations...
  25. ncbi Polymyositis-dermatomyositis-associated interstitial lung disease
    W W Douglas
    Division of Pulmonary and Critical Care Medicine, Department of Diagnostic Radiology, and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 164:1182-5. 2001
    We report findings in 70 patients with both diffuse interstitial lung disease and either polymyositis (PM) or dermatomyositis (DM)...
  26. ncbi Role of cytokines and chemokines in idiopathic inflammatory myopathies
    Boel De Paepe
    Department of Neurology and Neuromuscular Reference Center, Laboratory for Myopathology, Ghent University Hospital, Ghent, Belgium
    Curr Opin Rheumatol 21:610-6. 2009
    ..This review focuses on the most recent data and the new insight they provide for the disease mechanisms of dermatomyositis, polymyositis and sporadic inclusion body myositis.
  27. ncbi Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies
    J L De Bleecker
    Neurology Department, University Hospital, Gent, Belgium
    Neuromuscul Disord 9:239-46. 1999
    ..We immunolocalized TNF-alpha and its receptors in polymyositis, inclusion body myositis and dermatomyositis...
  28. ncbi T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells
    Andreas E R Fasth
    Rheumatology Unit, Center for Molecular Medicine L8 04, Karolinska University Hospital, Stockholm S 171 76, Sweden
    J Immunol 183:4792-9. 2009
    Dermatomyositis and polymyositis are disabling rheumatic diseases characterized by an appreciable number of T cells infiltrating muscle tissue. The precise phenotype, function and specificity of these cells remain elusive...
  29. ncbi Immunotherapy of myositis: issues, concerns and future prospects
    Marinos C Dalakas
    Imperial College London, Burlington Danes Building, Hammersmith Hospital Campus, Office E517, Du Cane Road, London W12 0NN, UK
    Nat Rev Rheumatol 6:129-37. 2010
    The main inflammatory myopathies within the myositis group include polymyositis, dermatomyositis and inclusion-body myositis (IBM)...
  30. ncbi Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis
    Yoshioki Yamasaki
    University of Florida, Gainesville, USA
    Arthritis Rheum 54:2004-9. 2006
    ..PL-7), alanyl (PL-12), glycyl (EJ), and isoleucyl (OJ), are closely associated with a subset of patients with polymyositis/dermatomyositis (PM/DM) complicated by interstitial lung disease (ILD)...
  31. ncbi Plasma cells in muscle in inclusion body myositis and polymyositis
    S A Greenberg
    Division of Neuromuscular Disease, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Neurology 65:1782-7. 2005
    Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral ..
  32. pmc Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study
    D Stockton
    Scottish Cancer Intelligence Unit, Information and Statistics Division, Trinity Park House, Edinburgh, EH5 3SQ
    Br J Cancer 85:41-5. 2001
    ..population-based cohort study of 705 patients hospitalized with a first diagnosis of dermatomyositis (DM) or polymyositis (PM) during 1982-1996 based on linkage of hospital discharge, cancer registration, and death records in ..
  33. ncbi Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis
    Tomoyuki Fujisawa
    Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
    J Rheumatol 32:58-64. 2005
    To assess the difference in clinical features and prognosis of patients with interstitial lung disease (ILD) comparing polymyositis (PM) and dermatomyositis (DM).
  34. ncbi Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy
    Paulius Venalis
    CMM Foundation, Karolinska University Hospital L8 04, 171 76 Stockholm, Sweden
    Rheumatology (Oxford) 53:397-405. 2014
    ..Such information will be important for the development of new therapies. ..
  35. ncbi Cutting edge issues in polymyositis
    Anna Ghirardello
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Italy
    Clin Rev Allergy Immunol 41:179-89. 2011
    ..IIM are classified into three major forms: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis...
  36. ncbi Monocyte/macrophage differentiation in dermatomyositis and polymyositis
    Kevin M Rostasy
    Department of Pediatrics, Division of Pediatric Neurology, University of Gottingen, Robert Koch Str 40, 37075 Gottingen, Germany
    Muscle Nerve 30:225-30. 2004
    ..groups of inflammatory myopathies, the muscle biopsies of 11 patients with dermatomyositis and 12 patients with polymyositis were studied using different macrophage markers...
  37. pmc Type 1 interferons and myositis
    Steven A Greenberg
    Department of Neurology, Division of Neuromuscular Disease, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Res Ther 12:S4. 2010
    ..In the group of disorders known as polymyositis, the study of blood samples suggests a potential role...
  38. pmc Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis
    M O Harris-Love
    George Washington University, School of Medicine and Health Sciences, Washington, DC, USA
    Rheumatology (Oxford) 48:134-9. 2009
    ..The secondary objectives included characterizing individual muscle group weakness and determining associations of weakness with functional status and myositis characteristics in this large cohort of patients with myositis...
  39. pmc Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies
    P Englund
    Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
    Am J Pathol 159:1263-73. 2001
    ..performed a systematic study of MHC class II antigen expression on muscle fiber membranes in muscle tissue from polymyositis and dermatomyositis patients in various stages of disease activity...
  40. ncbi Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment
    Armin Schnabel
    Department of Poliklinik für Rheumatologie, Universität Lübeck and Rheumaklinik, Bad Bramstedt, Germany
    Semin Arthritis Rheum 32:273-84. 2003
    ..prevalence, clinical characteristics, and treatment options of patients with interstitial lung disease (ILD) in polymyositis and dermatomyositis (PM/DM)...
  41. ncbi Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study
    Gabriel Cea
    MRC Biochemical and Clinical Magnetic Resonance Unit, Department of Biochemistry, Radcliffe Infirmary, University of Oxford, UK
    Brain 125:1635-45. 2002
    ..were used to investigate skeletal muscle metabolism in vivo in patients with dermatomyositis (DM) and polymyositis (PM) in order to evaluate the role of mitochondrial abnormalities in the pathogenesis and clinical expression ..
  42. pmc Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan
    Yi Ju Chen
    Department of Dermatology, National Yang Ming University, NO, 155, Sec, 2, Linong Street, Taipei 112, Taiwan
    Arthritis Res Ther 12:R70. 2010
    ..Our aim was to investigate the risk of cancer among IIM patients without a prior history of malignancies, in Taiwan...
  43. ncbi Renal involvement in patients with polymyositis and dermatomyositis
    T H Yen
    Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan
    Int J Clin Pract 59:188-93. 2005
    Renal involvement in patients with polymyositis (PM)/dermatomyositis (DM) is previously thought to be uncommon, but two main types of renal lesion have been described...
  44. ncbi Diagnostic criteria for polymyositis and dermatomyositis
    Frederick W Miller
    Lancet 362:1762-3; author reply 1763. 2003
  45. pmc Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis
    K Kurasawa
    Department of Internal Medicine II, Chiba University School of Medicine, Chiba City, Japan
    Clin Exp Immunol 129:541-8. 2002
    ..in corticosteroid-resistant and corticosteroid-sensitive interstitial pneumonitis (IP) in dermatomyositis (DM)/polymyositis (PM), we examined the activation markers and cytokine profiles of T cells in bronchoalveolar lavage fluids (..
  46. ncbi Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis
    Masahide Kubo
    Department of Dermatology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    J Am Acad Dermatol 47:148-51. 2002
    To determine the prevalence of 52-kd and 60-kd Ro/SS-A antibodies in Japanese patients with polymyositis/dermatomyositis, we examined serum samples from 61 patients with PM/DM, 10 patients with primary Sjögren's syndrome, and 25 healthy ..
  47. pmc Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle
    Jens Schmidt
    Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Brain 131:1228-40. 2008
    ..Expression of markers relevant for these pathomechanisms were analysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and non-myopathic muscle as controls, and cultured human myotubes...
  48. ncbi Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis
    I Yamadori
    Department of Clinical Pathology, National Okayama Medical Center, Japan
    Rheumatol Int 21:89-93. 2001
    ..obtained by surgical lung biopsy from 12 patients with interstitial pneumonia associated with untreated polymyositis/dermatomyositis (PM/DM)...
  49. ncbi Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients
    O Benveniste
    , , and Laboratoire de Neuropathologie, , Paris, France
    J Immunol 167:3521-9. 2001
    b>Polymyositis and dermatomyositis are diseases characterized by muscle weakness and muscle inflammatory infiltrates. Their pathogenesis remains unclear...
  50. ncbi Therapy of polymyositis and dermatomyositis
    Isabelle Marie
    Department of Internal Medicine, CHU Rouen, and INSERM U905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France
    Autoimmun Rev 11:6-13. 2011
    Because polymyositis and dermatomyositis (PM/DM) are uncommon conditions, few randomized placebo controlled studies have been performed in these patients...
  51. ncbi Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital
    C L Teh
    Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia
    Rheumatol Int 32:265-8. 2012
    We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58...
  52. ncbi The role of MRI in the assessment of polymyositis and dermatomyositis
    J Tomasová Studýnková
    Institute of Rheumatology, Na Slupi 4, 12850 Praha 2, Czech Republic
    Rheumatology (Oxford) 46:1174-9. 2007
    ..The aim of this study is to better evaluate the relationship of MR image of thigh muscles to clinical and histological parameters in patients with IIM...
  53. ncbi Dysferlin deficiency treated like refractory polymyositis
    Julien Vinit
    Department of Internal Medicine and Systemic Disease, Hopital General, Dijon University Hospital, 3 rue Faubourg Raines, 21033 Dijon Cedex, France
    Clin Rheumatol 29:103-6. 2010
    When an adult suffers from muscular symptoms, the diagnosis of polymyositis is often accepted if muscular biopsy reveals necrosis, fibrosis and cellular infiltrate with high expression of major histocompatibility complex class I...
  54. ncbi Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants
    Kazuki Takada
    Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Bunkyo ku, Tokyo 113 8519, Japan
    Autoimmunity 38:383-92. 2005
    Interstitial lung disease (ILD) is a common complication of polymyositis (PM) and dermatomyositis (DM), and accounts for a significant proportion of their morbidity and mortality because of the resistance to therapeutic agents including ..
  55. ncbi Prognosis and mortality of polymyositis and dermatomyositis patients
    A Airio
    Rheumatism Foundation Hospital, Heinola, Finland
    Clin Rheumatol 25:234-9. 2006
    The objective of this study was to assess the long-term outcome of polymyositis (PM) and dermatomyositis (DM) and the factors predictive of this outcome in a nationwide series in Finland...
  56. pmc The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis
    Hector Chinoy
    Rheumatic Diseases Centre, Hope Hospital, The University of Manchester, Salford, UK
    Ann Rheum Dis 66:1345-9. 2007
    There is a known association between myositis and cancer. The risk is greater in dermatomyositis (DM) than polymyositis (PM), although reliable methods to predict cancer risk in specific patients with myositis are not presently available...
  57. ncbi Interstitial lung disease in polymyositis and dermatomyositis
    I Marie
    Centre Hospitalier Universitaire de Rouen Boisguillaume, Rouen Cedex, France
    Arthritis Rheum 47:614-22. 2002
    To assess prevalence, characteristics, and long-term outcome of interstitial lung disease (ILD) in polymyositis (PM) and dermatomyositis (DM)...
  58. ncbi Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells
    Guillaume Page
    INSERM U403, Hopital Edouard Herriot, Lyon, France
    Arthritis Rheum 50:199-208. 2004
    To clarify the involvement of dendritic cells (DCs), chemokines, and proinflammatory Th1 cytokines in the pathogenesis of the chronic muscle diseases dermatomyositis (DM) and polymyositis (PM).
  59. ncbi Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study
    Y L Huang
    Department of Dermatology, National Yang Mind University, Taipei, Taiwan
    Br J Dermatol 161:854-60. 2009
    ..Previous studies showed that idiopathic inflammatory myopathies (IIM) carried an increased risk of cancers. However, no large-scale study of IIM has been conducted in the Chinese population...
  60. ncbi Interstitial lung disease in polymyositis and dermatomyositis
    Maryam Fathi
    Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Curr Opin Rheumatol 17:701-6. 2005
    The purpose of this review is to discuss current concepts regarding management of interstitial lung disease in polymyositis and dermatomyositis.
  61. pmc Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis
    Ronan J Walsh
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 56:3784-92. 2007
    ....
  62. ncbi Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis
    Adla B Hassan
    Arthritis Rheum 50:1013-5. 2004
  63. ncbi Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients
    Agnes Sparsa
    Department of Dermatology, University Hospital of Limoges, Limoges, France
    Arch Dermatol 138:885-90. 2002
    To identify potential risk factors and the yield of routine screens for early detection of malignancy associated with dermatomyositis (DM) and polymyositis (PM).
  64. ncbi Polymyositis, pulmonary fibrosis and malignant lymphoma associated with hepatitis C virus infection
    Y Aisa
    Department of Internal Medicine, Kitasato Medical Center Hospital, Kitamoto, Saitama
    Intern Med 40:1109-12. 2001
    b>Polymyositis has been associated with various viral infections, and a spectrum of immune-related diseases may occur with hepatitis C (HCV) infection. Both polymyositis and HCV infection may be accompanied by pulmonary fibrosis...
  65. pmc Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies
    Michael Mahler
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    Arthritis Res Ther 7:R19-29. 2005
    ..Thus, anti-SMP detection using ELISA represents a new serological marker with which to diagnose and discriminate between systemic autoimmune disorders...
  66. pmc Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis
    Geun Tae Kim
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Pusan National University, 1 10, Ami dong, Seo Gu, Busan, South Korea
    Clin Rheumatol 29:273-9. 2010
    ..IL17), and tumor necrosis factor alpha (TNFalpha) in muscle tissues of patients with dermatomyositis (DM) and polymyositis (PM)...
  67. ncbi Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study
    Csilla Andras
    Department of Oncology and Division of Clinical Immunology, 3rd Department of Internal Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary
    J Rheumatol 35:438-44. 2008
    To analyze clinical and laboratory data of patients diagnosed with dermato- or polymyositis between 1985 and 2006, retrospectively, with particular emphasis on association with malignant diseases.
  68. ncbi Polymyositis during pegylated alpha-interferon ribavirin therapy for chronic hepatitis
    Anil John
    Indian J Gastroenterol 26:147-8. 2007
  69. ncbi Polymyositis associated with infliximab treatment for rheumatoid arthritis
    Yukitomo Urata
    Mod Rheumatol 16:410-1. 2006
  70. ncbi A case of polymyositis and vasculitis induced by ovulation induction therapy with gonadotropin-releasing hormone
    Ivica Lazúrová
    Department of Internal Medicine, Medical Faculty, P J Safarik University Kosice, Trieda SNP 1, 04011, Kosice, Slovakia
    Clin Rheumatol 29:1327-30. 2010
    ..We report a case of vasculitis and histologically proven severe polymyositis developed 5 days after GnRH administration due to ovulation induction in an infertile patient with no previous ..
  71. pmc Malignancies in Korean patients with inflammatory myopathy
    Sang Won Lee
    Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
    Yonsei Med J 47:519-23. 2006
    The aim of this study was to assess the prevalence and the common type of malignancies in Korean patients with polymyositis (PM) and dermatomyositis (DM) and to evaluate the differences of clinical and laboratory findings between patients ..
  72. ncbi [Polymyositis induced or associated with lipid-lowering drugs: five cases]
    A L Fauchais
    Service de Medecine Interne A, CHU Dupuytren, 2, avenue Martin Luther King, 87042 Limoges Cedex, France
    Rev Med Interne 25:294-8. 2004
    ..Less than ten cases of dermatomyositis and polymyositis due to cholesterol-lowering drugs (CLD) have been previously reported...
  73. ncbi Arterial events in persons with dermatomyositis and polymyositis
    Annaliese Tisseverasinghe
    Department of Medicine, Internal Medicine, McGill University Health Centre, Montreal, QC, Canada
    J Rheumatol 36:1943-6. 2009
    To assess arterial events in dermatomyositis (DM) and polymyositis (PM), and associated factors.
  74. ncbi Polymyositis: an overdiagnosed entity
    Walter G Bradley
    Neurology 63:402; author reply 403. 2004
  75. ncbi Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma
    E Liozon
    Scand J Rheumatol 36:484-6. 2007
  76. ncbi Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide
    Uwe Lange
    Kerckhoff Clinic, University of Giessen, Department of Rheumatology and Clinical Immunology, Internal Medicine and Rheumatology, Bad Nauheim, Germany
    Autoimmunity 39:261-4. 2006
    Idiopathic inflammatory myopathies (IM), including dermatomyositis (DM) and polymyositis (PM), are a group of systemic rheumatologic diseases of unknown etiology characterized by chronic myositis...
  77. ncbi Epstein-Barr virus (EBV) associated lymphoepithelioma-like thymic carcinoma associated with paraneoplastic syndrome of polymyositis: a rare tumor with rare association
    Bhasker R Koppula
    Department of Nuclear Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    Clin Nucl Med 34:686-8. 2009
    ..We report a case of rare association of paraneoplastic syndrome of polymyositis with lymphoepithelioma-like thymic carcinoma...
  78. ncbi Association of polymyositis with rheumatoid arthritis
    E Martinez-Cordero
    National Institute of Respiratory Disease, Mexico, DF, Mexico
    Rheumatol Int 20:119-23. 2001
    The association of polymyositis (PM) and rheumatoid arthritis (RA) is described in a 40-year-old female Mexican patient who was studied for a long period of time...
  79. ncbi Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature
    G Cuomo
    Infectious Disease Section, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy
    Infection 41:859-62. 2013
    ..We report the case of a 38-year-old immunocompetent male with a polymyositis as the presenting manifestation of T. gondii infection...
  80. pmc A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
    Brandon W Higgs
    MedImmune, LLC, Gaithersburg, Maryland, USA
    Ann Rheum Dis 73:256-62. 2014
    ..of sifalimumab, an investigational anti-IFN-α monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by measuring neutralisation of a type I IFN gene signature (IFNGS) following drug exposure.
  81. ncbi Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
    C L Hill
    Boston University Arthritis Center, MA 02118-2394, USA
    Lancet 357:96-100. 2001
    BACKGROUND: Dermatomyositis and polymyositis are associated with cancer, but previous nationwide studies have not had sufficient cases to test the association between myositis and specific cancer types...
  82. ncbi [Dermatomyositis and polymyositis]
    J F Pellissier
    Laboratoire de Biopathologie Nerveuse et Musculaire, EA 3281, Faculte de Medecine de Marseille, France
    Rev Neurol (Paris) 158:934-47. 2002
    Dermatomyositis (DM) and polymyositis (PM) are the two main forms of idiopathic inflammatory myopathies...
  83. ncbi Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis
    Lin Yuan
    Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shenyang, China
    Clin Exp Rheumatol 31:428-32. 2013
    The purpose of this study is to determine whether soluble ST2 (sST2) and interleukin (IL)-33 is involved in dermatomyositis (DM) and polymyositis (PM).
  84. ncbi Polymyositis in patients taking antiviral clevudine therapy: a report of two cases
    Chung Yong Yang
    Department of 1Rehabilitation Medicine, Wonkwang University College of Medicine, Iksan, Korea
    NeuroRehabilitation 26:159-62. 2010
    ..Drug-induced polymyositis was suspected and the clevudine was finally withdrawn...
  85. pmc The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-gamma and lacking the SOCS-1 gene
    D Metcalf
    The Walter and Eliza Hall Institute of Medical Research and the Cooperative Research Centre for Cellular Growth Factors, Post Office, Royal Melbourne Hospital, 3050 Victoria, Australia
    Proc Natl Acad Sci U S A 97:9174-9. 2000
    ....
  86. ncbi Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features
    Sabiha Khan
    Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Center Tower, Suite 4100, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 37:143-58, v. 2011
    ..The 3 most common inflammatory myopathies are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis...
  87. pmc A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B
    Seung Won Lee
    The Hospital for Rheumatic Diseases, Hanyang University, 17 Haengdong dong, Seongdong Gu, Seoul 133 792, Korea
    J Korean Med Sci 17:141-3. 2002
    b>Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself...
  88. ncbi Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease
    Takahisa Gono
    Institute of Rheumatology, Tokyo Women s Medical University, Shinjuku ku, Tokyo 162 0054, Japan
    Rheumatology (Oxford) 49:1878-81. 2010
    ..To determine whether IL-18 is involved in the inflammation of DM and PM...
  89. ncbi Infectious complications in polymyositis and dermatomyositis: a series of 279 patients
    Isabelle Marie
    Department of Internal Medicine, CHU Rouen, Rouen, France
    Semin Arthritis Rheum 41:48-60. 2011
    To assess the prevalence and characteristics of severe pyogenic, nonpyogenic, and opportunistic infections in polymyositis and dermatomyositis (PM/DM) patients and to evaluate the predictive values for infections on clinical presentation ..
  90. ncbi Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation
    D R Couriel
    Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 30:543-6. 2002
    ..b>Polymyositis can occur in association with chronic GVHD and mimics the idiopathic form of the disease...
  91. pmc High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis
    Antti Airio
    Ann Rheum Dis 66:1404-5. 2007
  92. ncbi Polymyositis-dermatomyositis and infections
    Sandra Zampieri
    University of Padova, Division of Rheumatology, Department of Clinical and Experimental Medicine, Italy
    Autoimmunity 39:191-6. 2006
    ..This review focused on the possible role of infectious agents as triggers of autoimmunity in polymyositis (PM) and dermatomyositis (DM)...
  93. pmc Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA
    Brendan B Antiochos
    Department of Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 97239 3098, USA
    J Rheumatol 36:2704-10. 2009
    ..To retrospectively evaluate the association of idiopathic inflammatory myopathy (IIM) and malignancy in patients seen at 1 academic center over a 23-year period...
  94. ncbi Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice
    Takahiko Sugihara
    Tokyo Medical and Dental University, Tokyo, Japan
    Arthritis Rheum 64:2655-62. 2012
    ..discern the significance of interleukin-1 (IL-1) and tumor necrosis factor α (TNFα) as therapeutic targets in polymyositis (PM) by studying their involvement and the effects of their blockade in C protein-induced myositis (CIM), a ..
  95. ncbi Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab
    I Marie
    Rheumatology (Oxford) 44:1201-2. 2005
  96. ncbi Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis
    Adriana M E Sallum
    Department of Pediatrics University of São Paulo Medical School, Brazil
    Autoimmun Rev 5:93-100. 2006
    ..In contrast, VCAM-1 seems not to play a major role in JDM, as previously described in PM, DM and IBM. Adhesion molecule expression in JDM presents a differential characteristic when compared to PM, DM and IBM...
  97. pmc Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells
    Y Kikuchi
    Department of Internal Medicine, Saga Medical School, 5 1 1 Nabeshima, Saga 849 8501, Japan
    Ann Rheum Dis 60:1137-40. 2001
    ..It has previously been shown that RP105, a new B cell surface protein, is lost in activated human B cells...
  98. ncbi [New diagnostic criteria and measuring outcome in polymyositis and dermatomyositis]
    P Cherin
    Rev Med Interne 26:361-7. 2005
  99. ncbi [Current therapy for polymyositis and dermatomyositis]
    P Cherin
    Service de Medecine Interne I, Hopital Salpetriere, 47, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Rev Med Interne 29:9-14. 2008
    b>Polymyositis (PM), dermatomyositis (DM) and sporadic inclusion body myositis (s-IBM) are severe inflammatory muscle disorders of unknown cause, which may present life-threatening complications...
  100. ncbi [Polymyositis and dermatomyositis in adults. Tunisian multicentre study]
    S Toumi
    Service de Medecine Interne, CHU Sahloul, 4054, route de Ceinture, Sousse, Tunisia
    Rev Med Interne 30:747-53. 2009
    To study the clinical features and the outcome of polymyositis (PM) and dermatomyositis (DM) in Tunisia.
  101. ncbi Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis
    Helene Alexanderson
    Physical Therapy Department, Rheumatology Unit D2 07, Karolinska Institutet and Karolinska University Hospital, Solna, SE 171 76 Stockholm, Sweden
    Arthritis Rheum 55:114-22. 2006
    ..To revise the content of the Functional Index in myositis (FI) and to evaluate measurement properties of a revised FI...

Research Grants46

  1. Post-9/11 Incidence of Systemic Autoimmune Diseases in the FDNY Cohort
    Mayris P Webber; Fiscal Year: 2013
    ..syndrome (APS), systemic sclerosis (SSc;both diffuse and limited), inflammatory myositis (dermatomyositis, polymyositis, or inclusion-body myositis), Sjogren's syndrome, rheumatoid arthritis (RA), and non-RA inflammatory ..
  2. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
    ..determine whether rituximab is an effective treatment for adult and pediatric patients with dermatomyositis or polymyositis. Study hypotheses: 1) The time to improvement in Group A patients (receiving rituximab first) will occur ..
  3. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
    ..determine whether rituximab is an effective treatment for adult and pediatric patients with dermatomyositis or polymyositis. Study hypotheses: 1) The time to improvement in Group A patients (receiving rituximab first) will occur ..
  4. Multiparametric Classification of Muscle Damage in Inflammatory Myopathy
    Jane Park; Fiscal Year: 2013
    ..provided by applicant): The idiopathic inflammatory myopathies (IIM), including dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM), are autoimmune diseases resulting in muscle inflammation, weakness, ..
  5. Regulation of Pulmonary Fibrosis by CXCR3
    PAUL WESLEY NOBLE; Fiscal Year: 2013
    ..diseases such as those associated with connective tissue diseases such as scleroderma, rheumatoid arthritis and polymyositis. Pulmonary fibrosis also occurs in diseases that are not characterized by the same degree of interstitial ..
  6. Rheumatic Disease Sera: Probes of Disease Mechanisms
    Livia A Casciola-Rosen; Fiscal Year: 2012
    ..This application will identify these novel autoantigens, define their expression patterns in polymyositis and dermatomyositis and whether antigen expression and immune response are related in individual patients (..
  7. Effect of Aging on Lateral Transmission of Force in Skeletal Muscle
    Yingxin Gao; Fiscal Year: 2012
    ..with muscular dystrophy, muscle trauma, and injury and disease associated with ECM abnormities, such as polymyositis and sclerosis PUBLIC HEALTH RELEVANCE: The objective of this study is to examine the effect of aging on the ..
  8. Regulation and Gene Expression of Yeast Cytochrome c
    Fred Sherman; Fiscal Year: 2010
    ..have direct bearings to normal and pathological conditions of humans, including, for example, diseases such as polymyositis and scleroderma, which have diminutions in Rrp6p...
  9. INTEGRIN-DEPENDENT T CELL-MEDIATED MECHANISMS OF PULMONARY FIBROSIS
    Irina G Luzina; Fiscal Year: 2010
    ..in patients with autoimmune rheumatic diseases such as scleroderma, rheumatoid arthritis, dermatomyositis and polymyositis. The mechanisms of lung fibrosis are complex and poorly understood, and modern therapies are utterly inadequate...
  10. Idiopathic Inflammatory Myopathies: Improving Diagnosis and Predicting Outcomes
    Lisa Christopher Stine; Fiscal Year: 2010
    ..Allan Gelber, Antony Rosen, and Paul Plotz. IIM, including dermatomyositis, polymyositis, and inclusion body myositis, constitute the largest subset of acquired myopathies and often affect adults in ..
  11. The role of the dermatomyositis autoantigen MI-2 in muscle regeneration
    ANDREW L MAMMEN; Fiscal Year: 2012
    ..These diseases, which include dermatomyositis (DM) and polymyositis (PM), are characterized by muscle weakness, muscle inflammation, and autoantibodies...
  12. 2nd International Pathogenesis of Rare Neuroimmunologic Disorders
    Douglas Kerr; Fiscal Year: 2006
    ..in which there is an immunemediated[unreadable] injury of the nervous system that include the following: polymyositis, myasthenia gravis (MG),[unreadable] inflammatory polyneuropathies, transverse myelitis, HTLV-1 associated ..
  13. MICROSENSOR FOR INTRAMUSCULAR PRESSURE MEASUREMENT
    Kenton R Kaufman; Fiscal Year: 2013
    ..g. motor neuron disease, peripheral neuropathy), disorders of neuromuscular transmission (e.g. myasthenia gravis, Lambert-Eaton syndrome) and myopathies (e.g. muscular dystrophies, polymyositis, metabolic myopathies).
  14. Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients
    Chester V Oddis; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Autoimmune (AI) inflammatory muscle diseases (myositis) include polymyositis (PM), adult dermatomyositis (DM) and juvenile dermatomyositis (JDM)...
  15. Pathogenesis of Rare Neuroimmunologic Disorders
    Douglas Kerr; Fiscal Year: 2004
    ..There are a variety of rare neuroimmunologic disorders: polymyositis, myasthenia gravis, CIDP, transverse myelitis, TSP/HAM, stiff person syndrome, neuromyelitis optica, optic ..
  16. NUCLEAR PATHWAY FOR MESSENGER RNA DEGRADATION IN YEAST
    James Butler; Fiscal Year: 2002
    ..protein Rrp6p is a nuclear riboexonuclease homologous to an autoantigen produced in patients suffering from Polymyositis Scleroderma Overlap Syndrome (PM-Sc1), as well as to the Werner's and Bloom's syndrome proteins implicated in ..
  17. MOLECULAR BIOLOGY OF AUTOANTIBODIES
    ENG TAN; Fiscal Year: 1999
    ..lupus erythematosus, scleroderma, Sjogren's syndrome, mixed connective tissue disease, dermatomyositis and polymyositis, rheumatoid arthritis and drug-induced lupus...
  18. DEFINITION OF AUTOIMMUNE RESPONSES IN POLYMYOSITIS
    Morris Reichlin; Fiscal Year: 1992
    ..Thus, antibodies to Jol (histidyl tRNA synthetase) occur principally in polymyositis associated with interstitial lung disease...
  19. RHEUMATIC DISEASE--CORE CENTER
    Peter Schur; Fiscal Year: 1992
    ..definition of genes involved in the immunoregulation of ANA; (14) definition of the genes associated with in polymyositis; (15) determination of the clinical efficacy of dietary fish oil in rheumatoid and psoriatic arthritis and on ..
  20. MULTIPURPOSE ARTHRITIS CENTER
    Charles Christian; Fiscal Year: 1980
    ..The relationship between toxoplasmosis and the pathogenesis of polymyositis will be explored via studies of humoral and cellular immunity to Toxoplasma gondii...
  21. STRUCTURE AND AUTOIMMUNOGENIC POTENTIAL OF THE TH SNRNP
    Joseph Craft; Fiscal Year: 1992
    ..of these responses is closely linked to the pathogenesis of systemic lupus erythematosus, scleroderma, polymyositis, and related syndromes. The work will characterize a newly-identified snRNP known as the Th particle...
  22. AUTOANTIBODIES IN DERMATOMYOSITIS
    Ira Targoff; Fiscal Year: 1993
    Dermatomyositis (DM) and polymyositis (PM) are related autoimmune inflammatory myopathies, but there are significant clinical, pathological and immunological differences...
  23. IMMUNOPATHOGENESIS OF EXPERIMENTAL ALLERGIC MYOSITIS
    Abdolmohamad Rostami; Fiscal Year: 1993
    b>Polymyositis is an acquired inflammatory myopathy of man. Several lines of evidence suggest that immune mechanisms may be involved in the pathogenesis of the muscle fiber injury and degeneration in human polymyositis...
  24. AUTOANTIBODIES IN SLE AND POLYMYOSITITS
    Morris Reichlin; Fiscal Year: 1992
    Systemic Lupus Erythematosus (SLE) and Polymyositis (PM) are two disorders associated with disease specific autoantibodies. In SLE, a family of immune responses against several RNAprotein particles is characteristic of the disease...
  25. IMMUNE RESPONSE TO THYMIC ANTIGENS IN POLYMYOSITIS
    Morris Reichlin; Fiscal Year: 1980
    ..recently made observation that are antibody responses to thymic antigens specific for the dermatomyositis and polymyositis syndromes...
  26. MECHANISMS OF COXASACKIEVIRUS INDUCED POLYMYOSITIS
    Ronald Messner; Fiscal Year: 1992
    The induction of chronic polymyositis in mice by Coxsackievirus B1 (CVB1) provides a useful model of virus-induced autoimmunity and is highly relevant to human disease in that the clinical course and histopathology closely resemble human ..
  27. Gene Expression in Inflammatory Myopathies
    Steven Greenberg; Fiscal Year: 2005
    ..This work may provide further diagnostic approaches to these disorders and contribute to the understanding of their pathogenesis. ..
  28. A Pilot Study of Etanercept in Dermatomyositis
    Anthony Amato; Fiscal Year: 2007
    ..The information gained from this study is necessary in order to design larger therapeutic trials of etanercept and other agents in DM. ..
  29. Jo-1-specific T Cell Responses in Polymyositis
    DANA ASCHERMAN; Fiscal Year: 2007
    b>Polymyositis represents an autoimmune disease in which muscle is inappropriately targeted for T cell-mediated destruction...
  30. Spondyloarthritis 2006; The Unmet Needs
    John Reveille; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  31. Lymphoma in Autoimmune Disease: Consequence of Immune Suppression or Stimulation?
    Sasha Bernatsky; Fiscal Year: 2008
    ..Our proposed project will help identify patients at highest risk for lymphoma and provide guidance regarding initiation and maintenance of therapy to control SLE. [unreadable] [unreadable] [unreadable]..
  32. FAMILY STUDIES OF THE GENETICS OF ANKYLOSING SPONDYLITIS
    John Reveille; Fiscal Year: 2003
    ..abstract_text> ..
  33. Regulation of SPARC in Scleroderma Fibroblasts
    Xiaodong Zhou; Fiscal Year: 2007
    ..In addition, we will investigate whether exogenous SPARC can restore or increase fibrogenic effects of TGF-beta on cultured fibroblasts with or without suppression of the SPARC gene using recombinent SPARC protein. ..
  34. BORAGE OIL AND GINKGO BILOBA (EGb 761) IN ASTHMA
    MERRILL GERSHWIN; Fiscal Year: 2004
    ..It is hoped that findings from these studies will evolve relatively non-toxic therapeutic alternatives for attenuating bronchial hyperresponsiveness and inflammation in patients with asthma. ..
  35. BIOLOGY OF HUMAN INTRAEPITHELIAL LYMPHOCYTES
    Ellen Ebert; Fiscal Year: 2002
    ..These studies will determine the mechanism of IEL chemotaxis toward secreted products of ECs, why IL-15 is more potent than IL-2 in inducing LAK activity by IELs, and how IL-10 and IL-12 augment this activity. ..
  36. Pathogenesis of autoimmune myositis: Role of MHC Class 1
    Kanneboyina Nagaraju; Fiscal Year: 2009
    ..The MHC class I transgenic mice develop several features of human autoimmune polymyositis including myositis-specific autoantibodies...
  37. Nitric Oxide Metabolism in Statin-treated Pediatric SLE
    MARC LEVESQUE; Fiscal Year: 2006
    ..In addition, these DNA samples will constitute an important resource for future genetic analyses of pediatric SLE. [unreadable] [unreadable] [unreadable]..
  38. THE PATHOGENESIS OF AUTOIMMUNITY IN A MURINE MODEL OF PRIMARY BILIARY CIRRHOSIS
    MERRILL E GERSHWIN; Fiscal Year: 2010
    ..abstract_text> ..
  39. Peripheral and Central Mechanism of Pain in Patients with Fibromyalgia
    ROLAND M STAUD; Fiscal Year: 2010
    ..Either way, we will provide evidence that will characterize the role of local anesthesia, placebo analgesia, or both. Thus patients with FM and other similar pain syndromes may strongly benefit from the results of our study. ..
  40. Anti-Jo-1 Immune Responses in Autoimmune Myositis
    Stuart Levine; Fiscal Year: 2008
    ..abstract_text> ..
  41. NC-758 for Prevention of Recurrent Cerebral Hemorrhage
    Steven Greenberg; Fiscal Year: 2005
    ..In addition to testing a promising agent for CAA, the proposed study will generate the organization and pilot data to serve as a springboard for future trials of emerging anti-amyloid treatments. ..
  42. MECHANISM OF PAIN IN PATIENTS WITH FIBROMYALGIA SYNDROME
    Roland Staud; Fiscal Year: 2008
    ..In addition, our findings may contribute to the understanding of pain mechanisms related to other chronic pain disorders. ..
  43. Genetic Risks for Medication-Related Hemorrhagic Stroke
    Steven Greenberg; Fiscal Year: 2007
    ..This proposal is thus likely to form the foundation of a powerful, open-ended search for a panel of genetic tests to determine an individual's risk for Warfarin-related ICH. ..
  44. Oklahoma Specialized Center of Research in SLE
    Morris Reichlin; Fiscal Year: 2006
    ....